GlassScriptPhysician profile
Clarissa Barrettoko
NPI 1508012386
$596.55
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $211 · 2022: $18.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $97.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $80.81 | 2019-2020 | |
| Amgen INC. | $61.53 | 2020 | |
| Pfizer INC. | $59.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $54.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $53.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $51.99 | 2019-2020 | |
| Amarin Pharma, INC. | $32.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.93 | 2019 | |
| Abbvie INC. | $20.50 | 2019 | |
| Abbott Laboratories | $18.39 | 2022 | |
| Medtronic USA, INC. | $13.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarissa Barrettoko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.